Computational Insights into Bacteriocin Activity Against MRSA: Exploration of Bacteriocin Dynamics in Countering Methicillin-Resistant Staphylococcus Aureus (MRSA) and Overcoming Beta-Lactamase Enzyme Defense Mechanisms in the Antibiotic Resistance W

A higher risk of antibiotic-resistant microorganisms emerging has resulted from human overuse and inappropriate use of antibiotics in agriculture, the food industry, clinical use, and animal feed. By 2050, it's anticipated that there won't be any effective antibiotics available to treat infections that are resistant to multiple drugs if no new medications are developed to combat pathogens that have developed resistance to the existing drug. To stop the spread of infections brought on by drug-resistant pathogens, therapeutic alternatives to antibiotics are currently needed because the rate at which new antibiotics are being developed is insufficient to control microbial infection. Bacteriocins are the best alternatives to antibiotics because they can effectively combat drug-resistant bacteria because of their many advantages, including high stability at high temperatures and pH, low toxicity, and rapid killing. Bacteriocins are a type of narrow-spectrum antibacterial agent that has a bactericidal effect on closely related bacteria within the strain that produces them. It takes longer to conduct drug design studies, but currently, the in-silico method can be used to screen compounds to see if they have the potential to be used as a drug. Thus, the interactions between antimicrobial peptides produced by bacteria and p-lactamase were assessed using molecular docking. Eight bacteriocins were experimented against Beta-lactamase released by MRSA in which we found that Viridin exhibited the highest docking score of −8.6Kcal/mol. ADMET properties of Viridin revealed that it has the potential to be considered as a drug in treating multi-drug infections.